Efavirenz/lamivudine/tenofovir

Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Symfi among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.^[1][2][3] It combines efavirenz, lamivudine, and tenofovir disoproxil.^[3] As of 2019^[update], it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.^[4] It is taken by mouth.^[1][2][3]

Efavirenz/lamivudine/tenofovir

Combination of
Efavirenz	Non-nucleoside reverse transcriptase inhibitor
Lamivudine	Nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil	Nucleoside reverse transcriptase inhibitor
Clinical data
Trade names	Symfi, Symfi Lo
Other names	EFV/3TC/TDF
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a618028
License data	US DailyMed: Efavirenz_Lamivudine_Tenofovir disoproxil
Pregnancy category	Contraindicated
Routes of administration	By mouth
ATC code	J05AR11 (WHO)
Legal status
Legal status	US: ℞-only[1][2] In general: ℞ (Prescription only)
Identifiers
KEGG	D11392

Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.^[3] Severe side effects may include depression, psychosis, or osteonecrosis.^[3] In those with a history of epilepsy, it may increase the frequency of seizures.^[3] Greater care should also be taken in those with kidney problems.^[3] Its use during pregnancy appears to be unsafe.^[1][2]

It is on the World Health Organization's List of Essential Medicines.^[5] The combination received tentative approval in the United States in 2014,^[6] and was granted approval in February 2018.^[7][8] Its availability and importance is supported by Medecins Sans Frontieres.^[3] It is available as a generic medication.^[9][10][11]

References

1. "Symfi- efavirenz, lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 25 September 2021.
2. "Symfi Lo- efavirenz, lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 25 September 2021.
3. "Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults". World Health Organization (WHO). Archived from the original on October 26, 2015.
4. World Health Organization (July 2019). Policy brief: update of recommendations on first- and second-line antiretroviral regimens. World Health Organization. hdl:10665/325892. WHO/CDS/HIV/19.15. License: CC BY-NC-SA 3.0 IGO.
5. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
6. "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". U.S. Food and Drug Administration (FDA). Archived from the original on February 27, 2016. Retrieved 13 December 2017.
7. "Drug Approval Package: Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 15 August 2020.
8. "Drug Approval Package: Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 24 November 2018. Retrieved 15 August 2020.
9. "Office of Generic Drugs 2020 Annual Report". U.S. Food and Drug Administration (FDA). Retrieved 12 February 2021.
10. "Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 September 2021.
11. "Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 September 2021.

External links

• "Efavirenz". Drug Information Portal. U.S. National Library of Medicine.
• "Lamivudine". Drug Information Portal. U.S. National Library of Medicine.
• "Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine.
• "Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.